Expression of cyclooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases

Numerous studies have demonstrated that the levels of cyclooxygenase (COX), the enzyme that catalyzes the conversion of arachidonic acid to prostaglandin H 2, and of prostaglandins are higher in various tumors and cells during inflammation than in normal tissues. The aim of the present study was to...

Full description

Saved in:
Bibliographic Details
Published in:Breast (Edinburgh) 2003-02, Vol.12 (1), p.51-57
Main Authors: Sučić, M, Boban, D, Marković-Glamočak, M, Jakić-Razumović, J, Vrbanec, D, Ries, S, Gjadrov-Kuveždić, K, Čobanov, A.M, Podolski, P, Martinović, I, Erak, V, Budišić, Z, Ivrlač, R, Unušić, J
Format: Article
Language:English
Subjects:
Adult
Biopsy, Fine-Needle
breast cancer
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cyclooxygenase 2
cytooxygenase
Female
Fibroadenoma - metabolism
Fibroadenoma - pathology
Fibrocystic Breast Disease - metabolism
Fibrocystic Breast Disease - pathology
Humans
Isoenzymes - biosynthesis
Membrane Proteins
Middle Aged
Prostaglandin-Endoperoxide Synthases - biosynthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Numerous studies have demonstrated that the levels of cyclooxygenase (COX), the enzyme that catalyzes the conversion of arachidonic acid to prostaglandin H 2, and of prostaglandins are higher in various tumors and cells during inflammation than in normal tissues. The aim of the present study was to analyze whether COX-2 isoform expression was noticeably higher in fine-needle aspirates (FNA) from breast carcinoma than in FNA from fibroadenoma and fibrocystic breast tissue. COX-2 expression was detected by immunocytochemical (IC) staining and was analyzed by microscopic scoring and computer gray-scale analysis. Evaluation of COX-2 IC positivity in FNA from three groups of patients (nine with breast carcinoma, nine with fibroadenoma, eight with fibrocystic breasts) revealed high COX-2 IC positivity in the majority of patients with breast carcinoma and low or absent COX-2 IC positivity in patients with fibrocystic breast changes. In addition, low or medium COX-2 IC positivity was found in the majority of patients with fibroadenoma, only three of these patients having high COX-2 IC positivity.
ISSN:0960-9776
1532-3080
DOI:10.1016/S0960-9776(02)00281-3